Parkinson Drugs Need Better Trial Designs For Progression Claims, Advisory Panel Finds
Executive Summary
Use of linear analysis in a randomized-start trial is problematic for drugs for Parkinson’s disease, the Peripheral and Central Nervous System Drugs Advisory Committee told FDA Oct. 17.